News
HIV, Gilead Sciences and CVS Health
Digest more
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...
The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.
Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...
The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and Livdelzi.
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...
GlobalData on MSN18h
Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m
Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...
TipRanks on MSN12h
Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study
Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...
Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback